SUBLOCADE® (buprenorphine extended-release) in Patients Who Inject Opioids What is the background for this study? Adults with moderate or severe opioid use disorder (OUD) were randomized to SUBLOCADE monthly injections or placebo and studied for 24 weeks.

Participants receiving SUBLOCADE were given 2 monthly injections of 300 mg, followed by 4 monthly maintenance doses of 100 mg or 300 mg over the course of the study. What are the main findings?

  • Opioid-injecting users experienced continued improvement in the proportion of participants achieving abstinence with the 300 mg maintenance dose; no significant improvement was noted with the 100 mg maintenance dose.
  • Safety profiles of 300 mg and 100 mg maintenance doses appeared comparable, including potential hepatic safety events.


Weist et. Al. Examining the benefit of RBP-6000 300 mg versus 100 mg maintenance dose in opioid injectors. #W93. Presented at College on Problems of Drug Dependence (CPDD), June 23, 2021.

Sponsored by Indivior 



The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.


Last Updated on June 24, 2021 by Marie Benz MD FAAD